Determining the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in reducing the length of hospital stay of patients with Covid-19
Phase 1
- Conditions
- Covid-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20210222050457N1
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 188
Inclusion Criteria
Male or female patients aged 18 to 75 years with COVID-19 who have been diagnosed with a lung scan, PCR, or clinical examination.
Obtaining informed consent from the patient or patient caregiver to participate in the study
Exclusion Criteria
Cancer patients undergoing chemotherapy
Patients with immunodeficiency diseases receiving immunomodulators
Patients with uncontrolled heart, kidney or liver failure
Women who are pregnant or breastfeeding
Patients with low level of consciousness who are not able to inhale the spray
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of arterial oxygen saturation. Timepoint: Before and after intervention on a daily basis. Method of measurement: Pulse oximeter.;Severity of cough. Timepoint: Before and after intervention on a daily basis. Method of measurement: Based on the degree of severity.;Shortness of breath. Timepoint: Before and after intervention on a daily basis. Method of measurement: Based on the degree of severity.
- Secondary Outcome Measures
Name Time Method ength of stay in hospital. Timepoint: By day. Method of measurement: Number of days.;ICU admision time. Timepoint: By day. Method of measurement: Number of days.